Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
life sciences
national blog main
2
×
acetylon pharmaceuticals
ambys medicines
andrew berens
avapritinib
biotech
blueprint medicines
boston
boston top stories
cancer
cell therapy
clinical trials
constellation pharmaceuticals
deals
deciphera pharmaceuticals
gastrointestinal stromal tumor
gene therapy
genentech
gist
gleevec
holger willenbring
imatinib
ipo
jeffrey tong
juan carlos izpisua belmonte
keith dionne
liver disease
markus grompe
martin burke
national top stories
new york blog main
new york top stories
oregon stem cell center
proteon therapeutics
regorafenib
ripretinib
salk institute for biological studies
san diego blog main
What
deadly
2
×
aiming
ambys
announced
approval
big
biotech
blueprint
cancer
chasing
control
deal
debuted
deciphera
diseases
drug
fda
filing
formed
forms
future
gi
launch
liver
make
medicine
medicines
morning
new
pharamceuticals
plans
seek
startup
takeda
today
treatments
treats
tumor
type
unusual
Language
unset
Current search:
deadly
×
" national blog main "
×
@xconomy.com
4 years ago
Chasing Blueprint, Deciphera Plans FDA Filing for GI Cancer Drug
@xconomy.com
5 years ago
With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?